Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâre developing a new type of targeted therapy that ââŚrelies on knowledge from an RNA-based diagnostic instead of more traditional DNA-based diagnostics to determine if a patient with cancer is a candidate for our targeted therapy.â They believe that this type of diagnostic will help unlock targeted therapies for the 70% of cancer patients who do not have âdruggableâ genetic mutations in their DNA. So far, Nemucore has raised $7M from foundation grants and the National Cancer Institute; they have over 57 investors; and leading experts at Memorial Sloan Kettering and Moffitt Cancer Centers are set to perform their clinical trial. Plus, their leadership team has over 100 years of biopharmaceutical experience. The bottom line? Nemucore wants, with this campaign, to âcure AML together and open a new future of cancer care.â Source
No articles found.
BASi provides drug discovery and development services and analytical instruments t...
BASi provides drug discovery and development se...
Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused o...
Onconova Therapeutics, Inc. is a Phase 3-stage ...
We are a leading precision oncology company focused on helping conquer cancer glob...
We are a leading precision oncology company foc...
Syros is redefining the power of small molecules to control the expression of gene...
Syros is redefining the power of small molecule...
Spark Therapeutics, a fully integrated company, strives to challenge the inevitabi...
Spark Therapeutics, a fully integrated company,...
Reliv International, based in Chesterfield, MO, produces nutritional supplements t...
Reliv International, based in Chesterfield, MO,...
ASLAN Pharmaceuticals is a clinical-stage oncology-focused biotechnology company d...
ASLAN Pharmaceuticals is a clinical-stage oncol...
Join the National Investor Network and get the latest information with your interests in mind.